Corvus Pharmaceuticals, Inc.
(NASDAQ : CRVS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.50%43.970.9%$1186.44m
ABBVAbbVie, Inc. -0.22%107.121.9%$1023.77m
JNJJohnson & Johnson -0.23%164.480.7%$988.09m
MRKMerck & Co., Inc. 0.81%73.640.7%$914.30m
LLYEli Lilly & Co. -0.26%231.581.1%$588.95m
BMYBristol-Myers Squibb Co. -0.61%60.261.0%$575.61m
AZNAstraZeneca Plc 1.46%60.351.0%$353.10m
NVSNovartis AG -0.75%82.950.2%$156.40m
CRVSCorvus Pharmaceuticals, Inc. -3.27%6.800.7%$140.27m
GSKGlaxoSmithKline Plc -2.44%38.380.2%$135.32m
RGENRepligen Corp. -0.29%323.266.8%$123.14m
SNYSanofi -1.60%47.940.2%$122.20m
RPRXRoyalty Pharma Plc -0.08%37.100.1%$121.13m
VTRSViatris, Inc. 0.30%13.380.0%$107.54m
NVONovo Nordisk A/S -1.36%100.710.1%$101.76m

Company Profile

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The firm focuses on disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes B Cell Activator, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.